Explore Our Network

4M Therapeutics is a biotechnology company specializing in the discovery and development of targeted therapies for neuropsychiatric and neurodegenerative diseases such as bipolar disorder and Alzheimer's disease. Leveraging a human brain cell platform derived from induced pluripotent stem cells, the company advances small molecule and peptide drug candidates that modulate pathways involved in neuronal health. 4M Therapeutics integrates biomarker-driven drug development and strong academic collaborations to enable predictive and safe preclinical drug discovery, aiming to advance targeted CNS therapies with improved safety and efficacy profiles.

4TEEN4 Pharmaceuticals GmbH is a German biotech company pioneering precision medicine in critical care, with a mission to develop causal therapies for acute cardiovascular complications, particularly shock. The company focuses on targeting cDPP3, a key mediator in circulatory failure, and is advancing Procizumab, a first-in-class antibody, through clinical development. With a leadership team boasting over 150 years of pharma experience and a strong network of international researchers, 4TEEN4 aims to address unmet medical needs and improve patient outcomes where current therapies are inadequate.

AbViro is a Phase 2 clinical stage biotech company developing monoclonal antibody therapeutics for infectious diseases.

AccelerMED is dedicated to accelerating the adoption of innovative medical devices that enhance the quality and efficiency of patient care. With a focus on early-stage medical device companies, they provide commercial leadership and market development strategies to ensure successful commercialization and widespread adoption of novel technologies.

Accenture is a global professional services company with extensive capabilities in strategy and consulting, digital transformation, technology, and operations. The company aims to drive innovation and efficiency across various industries, helping clients navigate complex challenges and seize opportunities in a rapidly changing environment. Accenture is committed to creating positive change around the world and ensuring responsible business leadership for its people, clients, and communities. The company emphasizes continuous learning, responsible AI practices, and a culture of belonging and diversity.

Aceso Plasma develops investigational cold plasma medical devices focused on wound care, dermatology, and defense decontamination applications. Their flagship handheld device generates non-thermal, localized plasma from ambient air, supporting accelerated wound healing and reducing microbial and biofilm burden without increasing antimicrobial resistance. The technology has been validated in pre-clinical and investigational studies at multiple independent research institutes, including military and academic partners, and is currently advancing towards FDA clearance.

Action Medical Technologies is a pharmaceutical and medical device company focused on developing innovative solutions that integrate medications with advanced devices and injector systems to improve patient outcomes, particularly in austere prehospital environments.

Adaptyx Biosciences is developing a wearable platform for continuous monitoring of multiple biomarkers in dermal interstitial fluid from a single device at the point of need. Built on programmable molecular switch technology that can be reprogrammed across hormones, drugs, electrolytes, peptides, and proteins, it is a single platform adaptable to needs spanning Military Operational Medicine, Combat Casualty Care, Military Infectious Diseases, Clinical and Rehabilitative Medicine, and Chemical, Biological, and Radiological Defense. The platform draws on more than 17 years of pioneering research from our team at Stanford. We have prototype sensors ready for R&D today, and have already demonstrated continuous measurement of multiple biomarkers in humans, including multi-day free cortisol monitoring that captures the diurnal rhythm conventional single-timepoint tests cannot see.

Adipothera develops therapies that repair damaged tissue rather than manage symptoms. We target the stromal microenvironment to address the underlying biology of fibrosis and tissue remodeling. Our lead program addresses radiation-induced skin injury across both medical countermeasure and oncology supportive care settings, with an expanding pipeline in lymphedema and pathological bone formation.

AdraCard develops a proprietary, credit card-sized powder nasal spray platform for rescue medications used in sudden medical emergencies. Rescue medication only works if it is with the patient when the crisis occurs. By designing a device that fits seamlessly into a phone case, wallet, or pocket, AdraCard aims to solve the core problem of non-carriage and complacency, enabling constant access to life-saving medication in conditions such as anaphylaxis, seizure clusters, opioid overdose, hypoglycaemia, and migraine, beginning with adrenaline for anaphylaxis as its lead indication.

ADS, Inc. (Atlantic Diving Supply) is a leading value-added logistics and supply chain solutions provider serving all branches of the U.S. Military, federal, state and local government organizations, law enforcement agencies, first responders, partner nations, and the defense industry. Founded in 1997 in Virginia Beach, VA, ADS has grown into a Top 50 Department of Defense Contractor, recognized for its commitment to legendary customer service, broad procurement options, and innovative product and service offerings. The company is deeply rooted in its community, supporting military families, veterans, and first responders through scholarships, corporate giving, and ongoing service. ADS upholds the highest standards of business ethics, compliance, and quality, as demonstrated by its AS9100D, ISO 9001:2015, and ISO 14001:2015 certifications.

Advanced Functional Fabrics of America (AFFOA) is a nonprofit, public-private partnership and a U.S. Department of Defense-funded Manufacturing USA Innovation Institute. AFFOA is dedicated to revitalizing the U.S. textile industry by transforming traditional fibers, yarns, and textiles into sophisticated, integrated, and networked devices and systems. The organization aims to bridge the gap between early-stage technology and commercialization, leveraging its expertise and membership ecosystem to advance textile-based products with transformative capabilities for defense and consumer markets.

Advanced Light Devices manufactures the patent pending Hemealumen Polychromatic Device Innovative Solutions for Treating Infectious and Neurodegenerative Diseases Company Overview Advanced Light Devices is a pioneering company established in the early 2000s, dedicated to developing advanced medical technologies for the treatment of a range of diseases. With a vision to revolutionize healthcare, the company focuses on innovative therapies that utilize light-based technology to address complex medical challenges. The Hemealumen Polychromatic Device At the core of Advanced Light Devices' portfolio is the Hemealumen Polychromatic Device, a state-of-the-art medical tool designed to combat both viral and bacterial diseases. In addition, this device is being used as a therapeutic option for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Applications in Infectious Disease Treatment The Hemealumen Polychromatic Device has demonstrated effectiveness in treating a variety of infectious diseases, including: Malaria Dengue fever COVID-19 Zika virus Shingles By utilizing targeted polychromatic light, the device disrupts the replication and survival mechanisms of pathogens, offering a non-invasive and innovative approach to disease management. Blood Treatment During Transfusions The Hemealumen Polychromatic Device is also used to treat blood during transfusions, effectively eliminating bacteria and viruses. This process enhances the safety of blood transfusions, reducing the risk of transfusion-transmitted infections and improving patient outcomes. Impact on Neurodegenerative Diseases Beyond infectious diseases, the device shows promise in the management of neurodegenerative conditions such as ALS and Parkinson's disease. Its mechanism of action may help reduce the progression of these disorders, though further research is ongoing to fully understand its therapeutic potential. Conclusion Advanced Light Devices, through the Hemealumen Polychromatic Device, is at the forefront of medical innovation. Their commitment to developing effective treatments for both infectious and neurodegenerative diseases position them as a leader in the field of light-based medical technology.

Advanced Material Development Inc. is a US-headquartered global defense technology company specializing in nanomaterial-based solutions for stealth, shielding, and sensing in defense and aerospace applications. The company focuses on engineering lightweight, scalable, and sustainable materials that deliver operational advantages for military and security sectors. With collaborative R&D partnerships involving leading universities and industry, it brings innovations in radar absorption, EMI shielding, laser defense, and chemical sensing platforms. The company operates in the United States and United Kingdom, maintaining strong compliance, environmental, and security standards.

Advanced Materials and Devices, Inc. (AMAD) is a leader in the development of wearable blast sensors and controllable vehicle suspension technologies. The company is dedicated to advancing safety and protection through innovative solutions, particularly in the field of blast measurement and safety technology. AMAD's mission is to lead advancements in these areas, providing state-of-the-art solutions for both military and commercial applications.

The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.

Advanced Virology specializes in high-fidelity production and engineering of research-grade virus stocks using reverse genetics. The company supports customizable solutions across a broad range of viral families—including wild-type, chimeric, and reporter-expressing viruses. Comprehensive quality assurance and documentation protocols are applied to each batch. Custom services enable the development of tailored virus variants, molecular tags, and reporters to meet research and assay needs.

Aegilys specializes in the development of advanced electrochemical sensors for real-time chemical and biological threat detection as well as physiological monitoring. Integrating cutting-edge materials science, nano-engineering, and edge analytics, the company supports operational readiness, safety, and performance for defense, security, and elite athletic markets. Headquartered in Rockville, Maryland, Aegilys is recognized for its multidisciplinary expertise and innovation in sensor technology for demanding environments.

AegisCN LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute neurological injury and stroke. The company’s lead therapeutic candidate, CN-105, is a proprietary neuroprotective peptide designed to reduce inflammation, limit secondary brain injury, and improve recovery following central nervous system events. AegisCN’s development efforts have centered on high-impact medical conditions with significant unmet need, including intracerebral hemorrhage (hemorrhagic stroke) and traumatic brain injury (TBI). CN-105 has advanced through Phase 1 and Phase 2 clinical studies, reflecting the company’s commitment to translating cutting-edge neuroscience into real-world treatment options for patients and providers.

AeroVironment designs, develops, and deploys uncrewed aerial, ground, and loitering munitions systems, as well as advanced autonomy and mission software for defense, security, and exploration applications. The company has a track record of pioneering innovations in robotics, high-altitude platforms, and planetary flight systems, delivering scalable and adaptable technologies for complex and demanding missions across multiple domains.

AiRANACULUS is a leader in Intelligent RF and Networking Solutions, providing advanced technologies for applications from Space to Smart Cities. The company focuses on creating spectrum-aware technologies that optimize radio and sensor systems for performance in complex environments, leveraging expertise in signal processing, cybersecurity, and networking.